Gene Company to Distribute Partek's Software in China
Gene Company will distribute Partek’s software in China, Partek said last week.
Under the agreement, Hong Kong-based Gene Company will sell, market, and support Partek’s Genomics Suite, Discovery Suite, QSAR Solution, and the Partek Screening Solution.
Partek’s software suites help analyze gene expression, chromosomal copy numbers, promoter tiling, as well as high-density SNP arrays, drug-discovery data and visualization, and high-throughput screening.
Financial terms of the agreement were not released.
Epidauros Licenses CYP2D6 IP to Luminex Molecular Diagnostics, Nanogen, and Nanosphere
Epidauros said this week that it has signed non-exclusive licensing agreements for its biomarker patents with Luminex Molecular Diagnostics, Nanogen, and Nanosphere.
The agreements will allow the companies to use Epidauros' CYP2D6 IP, which is involved in metabolism of roughly 25 percent of “the most commonly prescribed drugs,” as a predictive marker for responsiveness and adverse drug reactions, the company said.
Financial terms of the agreement were not disclosed.
SIRS Lab Ditches In-House Gene-Expression Platform for Illumina System
SIRS-Lab, a Jena, Germany-based diagnostics company that also sells gene-expression services, has adopted an Illumina gene-expression system and has made the decision to discontinue use of the internally developed gene expression system it had offered over the past five years, according to a company scientist.
“Before we were making our own arrays, but we decided to stop this business,” SIRS-Lab’s Julien Landre told BioArray News this week. “The Illumina platform is new. We’ve been in this business for quite awhile, and when it comes to gene expression, this platform suits us best,” he said.
Current SIRS-Lab gene-expression service customers include the William Harvey Research Institute in London and Charité University in Berlin, according to a statement from the company.
SIRS-Lab currently has a separate diagnostic discovery program focusing on sepsis, but Landre said that the company has not made a decision on what platform it will use for future tests.
U Pittsburgh Will Use Arrays to Hunt Markers Linked to Lung Disease
Researchers from a University of Pittsburgh School of Medicine center are recruiting several hundred patients with idiopathic pulmonary fibrosis to study the clinical, biochemical, and genetic changes that may occur as the result of treatment or progression of the disease, the center said last week.
The study, conducted at the Dorothy P. & Richard P. Simmons Center for Interstitial Lung Disease, aims to identify biomarkers in blood samples that can be used to develop a simple blood-based diagnostic and prognostic test for the disease.
Investigators will collect and analyze blood samples from a large cohort of people with IPF for a period of up to five years as they receive treatment according to the latest guidelines. The investigators will use arrays to develop relevant gene-expression signatures for IPF patients, the center said.